Figure 5b from the paper shows the difference between tumors treated with just an antibody and vehicle (solution) or with trametinib and rigosertib and a CD40 agonist. Credit: Nature Communications (2026). DOI: 10.1038/s41467-025-67315-1
For patients with advanced melanoma without BRAF mutation who no longer respond to immune…